We are thrilled to announce the first healthy volunteer participants have been dosed in the Phase 1 clinical trial of APG808, our novel half-life extended IL-4Rα antibody for the treatment of #COPD and other inflammatory diseases. We expect to report interim subcutaneous safety and pharmacokinetic data in the second half of this year. CEO Michael Henderson shares more below. https://lnkd.in/e3tQyXmD
Congratulations
Congratulations Wendy to you and the entire team!
very exciting!
Late Discovery Project Manager, Early CMC Development Drug Substance Management, Project Manager
4moCongratulations on your Phase 1 positive interim data. May you have continued success as APG808 proceeds forward in testing.